Chugai transfers Monilac rights to Maruishi

22 July 2024

Japanese drugmaker Chugai (TYO: 4519) today announced it will transfer to Maruishi Pharmaceuticals the business in Japan concerning the physiological intestinal function improving and hyperammonemia drug Monilac for which Chugai holds the manufacturing and marketing authorization in Japan.

Chugai, which is majority-owned by Swiss pharma giant Roche (ROG: SIX), has been marketing Monilac and providing information in Japan since 1975. In consideration of the maturity of its product lifecycle, Chugai has been considering its future domestic marketing.

As a result of discussions between Chugai and Maruishi, it was agreed that Chugai would transfer all assets relating to Monilac in Japan, including manufacturing and marketing authorization and intellectual property rights such as trademarks, to Maruishi, and Maruishi would thereafter be responsible for sales of the drug. Maruishi, which has strengths in the basic drug field, will strive to maximize the value of Monilac through synergy with its existing products.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical